



NEWS RELEASE

Mast Therapeutics To Present At 36th Annual Canaccord Genuity Growth Conference On August 10

2016-08-02

SAN DIEGO, Aug. 2, 2016 /PRNewswire/ -- **Mast Therapeutics, Inc.** (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 36th Annual Canaccord Genuity Growth Conference on Wednesday, August 10, 2016 at 4:30 p.m. Eastern time in the San Francisco Room at the InterContinental hotel in Boston.

Interested parties can access a live audio webcast on the Mast Therapeutics web site at www.masttherapeutics.com. An archived presentation will be available on the web site for 30 days.

About Mast Therapeutics

Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is developing two clinical-stage investigational new drugs for serious or life-threatening diseases and conditions. Vepoloxamer, the Company's lead product candidate, is in Phase 3 clinical development for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in Phase 2 clinical development for the treatment of patients with heart failure. Enrollment in the Company's 388-patient Phase 3 study of vepoloxamer in patients with sickle cell disease, known as the EPIC study, was completed earlier this year. Enrollment in the Company's Phase 2 study of vepoloxamer in patients with chronic heart failure is ongoing. AIR001, the Company's second product candidate, is in Phase 2 clinical development for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). Enrollment in Phase 2 studies of AIR001 in patients with HFpEF are ongoing, including a 100-patient, multicenter, randomized, double-blind, placebo-controlled, Phase 2 study in patients with HFpEF being conducted by the Heart Failure Clinical Research Network. More information can be found on the Company's web site at www.masttherapeutics.com. (Twitter: @MastThera)

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Logo - <http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/mast-therapeutics-to-present-at-36th-annual-canaccord-genuity-growth-conference-on-august-10-300307534.html>

SOURCE Mast Therapeutics, Inc.

Mast Therapeutics, Ioana C. Hone (ir@mastthera.com), 858-552-0866 Ext. 303